Overview of recent advances in metastatic triple negative breast cancer

Table 4 Phase III first line metastatic immunotherapy + chemotherapy

	IMpassion130 (PD-L1 inhibitor)	Keynote-355 (PD1 inhibitor)	IMpassion131 (PD-L1 inhibitor)
Drugs	Atezolizumab/nab-paclitaxel vs placebo/nab-paclitaxel	Pembrolizumab + chemotherapy (nab-paclitaxel or paclitaxel or gemcitabine/carboplatin vs placebo + chemo	Atezolizumab/paclitaxel vs placebo/paclitaxel
ITT (N)	451 vs 451 (1:1 randomisation)	566 vs 281 (2:1 randomisation)	430 vs 221 (2:1 randomisation)
Inclusion	≥ 1 yr DFI	≥ 6 mo DFI	≥ 1 yr DFI
PD-L1 status	IC [positive (≥ 1%) vs negative (< 1%)]	CPS [positive (≥ 1%) vs negative (< 1%)]	IC [positive (≥ 1%) vs negative (< 1%)]
	SP142 antibody ventana platform	PD-L1 IHC 22C3 pharmDx kit	SP142 antibody ventana platform
Primary endpoints	PFS and OS in ITT population	PFS and OS by PD-L1 status (CPS ≥ 10 and ≥ 1) in ITT	PFS and OS in PD-L1 positive cohort
Median FU	18.0 mo (ASCO 2019)	25.9 mo and 26.3 mo (ASCO 2020)	8.6 and 9 mo (ESMO 2020)
PFS in PD-L1 +	7.5 mo vs 5 mo	9.6 mo vs 5.6 mo	5.7 mo vs 5.6 mo
OS in PD-L1 +	25.4 mo vs 17.9 mo	Awaited	22.1 mo vs 28.3 mo

PD-1: Programmed death 1; PD-L1: Programmed death-ligand 1; ITT: Intention-to-treat; DFI: Disease Free Interval; IHC: Immunohistochemistry; OS: Overall survival; ASCO: American Society of Clinical Oncology; ESMO: European Society of Medical Oncology; PFS: Progression free survival; CPS: Combined positive score.